Skip to content
i2E
  • Programs
    • For Startups
      • E3
      • Bridge2
      • OCN
    • For Students
      • Entrepreneur’s Cup
    • For Corporations
    • For Investors
  • Client Portfolio
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Events
  • Contact
  • Media
  • Programs
    • For Startups
      • E3
      • Bridge2
      • OCN
    • For Students
      • Entrepreneur’s Cup
    • For Corporations
    • For Investors
  • Client Portfolio
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Events
  • Contact
  • Media
Search

Patent protection: Extension helps

Get in Touch

By Sarah Terry-Cobo

Courtesy of The Journal Record

OKLAHOMA CITY – Lijun Xia and Rodger McEver received some good news about their cancer research this year. The patent they initially received for a possible leukemia treatment in 2004 was extended to 2024.

Patent protection is essential for helping get research out of the laboratory at the Oklahoma Medical Research Foundation, and eventually to patients battling cancer and other diseases.

The nonprofit OMRF doesn’t have the billion dollars needed to develop and test new therapies, President Stephen Prescott said. So it must work with pharmaceutical companies, which can invest in the discoveries made in OMRF’s lab to manufacture treatments at the scale needed for clinical trials.

It can take 15 years, on average, before a lab discovery is approved as a medicine or a treatment. When a scientist receives 20-year exclusivity rights on a treatment, that allows pharmaceutical companies time to develop the necessary manufacturing and clinical trial tests the U.S. Food and Drug Administration require before new drugs or treatments can be approved. This gives a pharmaceutical company a path to profitability, Prescott said.

The FDA regulatory process is expensive and time-consuming. Pharmaceutical companies must prove that discoveries in the lab don’t do more harm than good, which is particularly important for cancer treatments, said Jim Bratton, executive director of the University of Oklahoma Office of Technology Development.

“When researchers find new ways to crack the code, it’s encouraging for them to find ways to lengthen the opportunity for applying that innovation to a commercial setting,” he said.

Xia and McEver have discovered a way to make bone marrow transplants more successful. Their technology modifies stems cells found in umbilical cord blood to use in the transplants. However, there are challenges in getting those cells to work, Xia said.

One hurdle is getting stem cells to flow into the marrow once it is injected into the bloodstream. So the scientists found an enzyme that helps the blood cells hone in on and adhere to the marrow. Typically, cord blood cells adhere to bone marrow about 30 percent of the time. The discovery modifies cells so it adheres 99 percent of the time, he said.

When stem cells adhere to bone marrow, it can decrease recovery time and reduce the chance of infection or excessive bleeding, Xia said. Those savings can be dramatic for patients. A single day’s hospital stay in a bacteria-free environment necessary for bone marrow transplants can cost an average of $10,000.

The OMRF has a licensing agreement with Carlsbad, Calif.-based Targazyme to develop the enzyme on a commercial scale. The pharmaceutical company is working with MD Anderson to use the treatment in a clinical trial. Targazyme must raise more money to conduct a second phase of clinical trials.

But if the FDA approves the treatment, it could be used in more than just leukemia patients, Xia said. Stem cell treatment therapy can also be used to treat heart attack and stroke patients.

Bratton said patent protection helps foster the relationships between research institutions like OMRF or the OU Health Sciences Center and major pharmaceutical companies.

“We’re doing the out-of-the-box thinking, applying creative and innovative approaches to understand what is causing cancer to thrive or survive and proliferate,” he said.

The need to meet next quarter’s earnings expectations drives pharmaceutical companies to work with research institutions, which think about science holistically.

“It’s not just how do we kill the cancer, it’s how do we save the patient,” Bratton said.

Click here to read the article at the Journal Record website (subscription required).

 

 

More News

Loading...
Blog, Featured, News
12.16.24

MidAmerica and i2E Announce Award Winners

Read more
Blog, Featured, News
11.21.24

i2E & Plains Ventures Surpasses $100M Milestone in Total Investments

Read more
Blog
09.30.24

i2E Receives 2024 Excellence in Economic Development Award from IEDC

Read more
Blog
06.18.24

Bridge2 Demo Day Returns, Highlighting Promising Oklahoma Startups

Read more
Blog, Entrepreneur's Cup Featured, Entrepreneur's Cup News
05.13.24

Student Entrepreneurs Triumph at 20th Anniversary Entrepreneur’s Cup, Winning $158,000 in Prizes

Read more
Default Featured Image
Blog, Entrepreneur's Cup News
04.24.24

Beyond the Cup: Tracking Success Stories from the Entrepreneur’s Cup Series – Jessica Kinsey

Read more
Default Featured Image
Blog, Entrepreneur's Cup News
04.23.24

Beyond the Cup: Tracking Success Stories from the Entrepreneur’s Cup Series – Nathan Fountain

Read more
Default Featured Image
Blog, Entrepreneur's Cup Featured, Entrepreneur's Cup News
04.23.24

Beyond the Cup: Tracking Success Stories from the Entrepreneur’s Cup Series – Srijita Ghosh

Read more
Default Featured Image
Blog, Entrepreneur's Cup Featured, Entrepreneur's Cup News
04.18.24

Beyond the Cup: Tracking Success Stories from the Entrepreneur’s Cup Series – MaxQ

Read more
Blog, i2E
01.30.24

i2E Celebrates Success of Inaugural Bridge2 Demo Day

Read more
Blog, i2E, News
12.18.23

i2E and MidAmerica Industrial Park announce award winners for high school entrepreneurship program

Read more
Blog, i2E
12.13.23

Entrepreneur’s Cup Marks 20 Years: Reimagined Competition and Brand – Same Entrepreneurial Spirit

Read more
i2E

Oklahoma City Office

201 Robert S Kerr Ave, Suite 600
Oklahoma City, OK 73102
+1 (405) 235.2305

Tulsa Office

12 N. Cheyenne Ave, Suite 112
Tulsa, OK 74103
+1 (918) 582.5592

  • Client Portfolio
  • About Us
  • Media
  • Events
  • Contact
  • Resources
  • Funding
  • Venture Advisory

© 2025 i2E Privacy Policy

Follow us:

Linkedin Twitter Facebook Instagram Youtube

Programs

  • For Startups
    • E3
    • Bridge2
    • OCN
  • For Students
    • Entrepreneur’s Cup
  • For Corporations
  • For Investors
  • For Startups
    • E3
    • Bridge2
    • OCN
  • For Students
    • Entrepreneur’s Cup
  • For Corporations
  • For Investors
  • Client Portfolio

Services

  • Access to Funding
  • Venture Advisory Services
  • Events
  • Contact
  • About
  • Our Values
  • Our Team
  • Board of Directors
  • Corporate Partners
  • Media
i2E